Teclistamab: Mechanism of action, clinical, and translational science

Yue Guo(Janssen (United States)), Danièle Ouellet(Janssen (United States)), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Natalia A. Quijano Cardé(Sheba Medical Center), Clarissa Uhlar(University of Pennsylvania), Lijuan Kang(Chinese Academy of Sciences), Margaret Doyle(Janssen (Ireland)), Katherine Chastain(Janssen (United States)), Nahor Haddish‐Berhane, Kodandaram Pillarisetti(Johnson & Johnson (United States)), Jennifer Smit(Janssen (United States)), Rachel Kobos(Centre Hospitalier Universitaire de Nantes)
Clinical and Translational Science
January 1, 2024
10.1111/cts.13717
Cited by 29

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Serum amyloid A, the major vertebrate acute‐phase reactant
|European Journal of Biochemistry|1999|1.1k
Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune Responses
|Science|2007|852
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
|Journal of Clinical Oncology|2022|647